Biological medication for rheuma

No definition available.

Endpoint definition

↥
FinnGen phenotype data
diagram bullet diagram downward connector

Filter registries KELA purch., KELA reimb.

Medicine purchases: ATC L04AA24|L04AC03|L04AB04|L04AB01|L04AB06|L04AB02|L04AB05|L04AA26|L01XC02|L04AC10|L04AC07|L04AC05
Medicine purchases: ATC: other data required >3 instances required

Check pre-conditions None

Include endpoints None

Check conditions None

Apply sex-specific rule None

diagram downward connector RX_RHEUMA_BIOLOGICAL

Extra metadata

First used in FinnGen datafreeze DF5

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 2648 1615 1033
Unadjusted prevalence (%) 1.02 1.10 0.91
Mean age at first event (years) 47.02 46.84 47.32

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.07 4.78 [2.85, 8.02] 3.1e-9 29
15 years 0.03 4.78 [2.85, 8.02] 3.1e-9 29
5 years 0.00 4.29 [2.25, 8.17] 9.3e-6 13
1 year - - - -

Correlations

↥

Index endpoint: RX_RHEUMA_BIOLOGICAL – Biological medication for rheuma
GWS hits: 10

Survival analyses between endpoints

↥

Plot

before Biological medication for rheuma
after Biological medication for rheuma

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Biological medication for rheuma

↥